Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-12 vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of persistent, moderate to severe chronic pain in opioid-tolerant patients requiring around-the-clock analgesic therapy for an extended period,Management of breakthrough pain in opioid-tolerant patients
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is approximately 20–27 hours (range 13–44 hours) after transdermal patch removal; prolonged in elderly, hepatic impairment, and with continuous use due to drug accumulation in skin and adipose tissue.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Fentanyl is primarily metabolized in the liver via CYP3A4-mediated N-dealkylation to norfentanyl, an inactive metabolite. Approximately 75% of the dose is excreted in urine, mainly as metabolites, with less than 10% as unchanged drug.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: approximately 75% as metabolites (primarily norfentanyl and other inactive metabolites) and <10% as unchanged fentanyl; fecal: approximately 9%; biliary: minor.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 80–85% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 6 L/kg (range 3–8 L/kg) after intravenous administration; high Vd indicates extensive tissue distribution and accumulation in fat and muscle.
4-6 L/kg; large Vd indicates extensive tissue distribution
Transdermal: approximately 92% relative to intravenous; absolute bioavailability is about 30–40% (due to first-pass metabolism, but transdermal bypasses hepatic first-pass, hence high relative bioavailability).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 30-89 m L/min: start at 50% of usual initial dose; GFR <30 m L/min: avoid use or start at 50% of usual dose with cautious titration. Not recommended in dialysis patients.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh class A: start at 50% of usual initial dose; Child-Pugh class B: start at 25% of usual dose; Child-Pugh class C: avoid use due to extreme risk of toxicity.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
For pediatric patients aged 2-16 years currently receiving and tolerant to opioids (equivalent to at least 60 mg oral morphine/day): initial fentanyl dose (mcg/h) based on previous 24-hour opioid requirement using standard conversion; apply patch every 72 hours. For opioid-naive pediatric patients: not recommended.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at 50% of usual adult starting dose (e.g., 12 mcg/h every 72 hours) due to increased sensitivity and reduced clearance; titrate cautiously with longer intervals between dose adjustments.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; ABUSE POTENTIAL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISK OF MEDICATION ERRORS; and RISK OF SERIOUS HARM OR DEATH WITH CONCOMITANT USE OF CYP3A4 INHIBITORS. DURAGESIC is contraindicated in the management of acute or intermittent pain, or in opioid-non-tolerant patients. Accidental exposure to DURAGESIC may result in fatal respiratory depression.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Life-threatening respiratory depression, especially during initiation or dose escalation,Accidental exposure can be fatal,Risk of abuse, misuse, and addiction,Risks from concomitant use with benzodiazepines or other CNS depressants,Neonatal opioid withdrawal syndrome with prolonged use during pregnancy,Risks of medication errors (e.g., confusion with other fentanyl products),Serotonin syndrome with concomitant serotonergic drugs,Adrenal insufficiency,Severe hypotension,Risks in patients with head injury or increased intracranial pressure,Application site reactions and skin irritation,Wound healing complications in patients with surgical wounds
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Opioid non-tolerant patients,Management of acute or intermittent pain,Postoperative pain management,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to fentanyl or any components of the system
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid or limit grapefruit juice as it inhibits CYP3A4, increasing fentanyl levels and risk of adverse effects. No other significant food interactions. Alcohol should be avoided as it enhances central nervous system depression.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Pregnancy category C. First trimester: Limited data; theoretical risk of neural tube defects if folate deficiency exacerbated. Second and third trimesters: Risk of neonatal withdrawal syndrome, respiratory depression, and decreased fetal growth; avoid prolonged use near term.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Fentanyl transfers into breast milk; M/P ratio approximately 0.17-0.47. Caution: risk of infant sedation and respiratory depression. Consider benefits vs risks; avoid if infant is <3 months or has respiratory compromise.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Pregnancy increases clearance of fentanyl by 35-50% in second and third trimesters; consider dose increase guided by pain response; postpartum clearance returns to prepregnancy levels within 48 h, requiring dose reduction.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
DURAGESIC-12 (fentanyl transdermal system) is indicated for opioid-tolerant patients only. Do not initiate in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-irradiated skin on flat surface such as chest, back, flank, or upper arm. Avoid heat sources (heating pads, hot tubs, fever) which increase absorption. Monitor for constipation and respiratory depression, especially at start and dose titration. Not for acute pain or post-op use in opioid-naive patients.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Apply patch to clean, dry, non-hairy skin; do not cut or damage the patch.,Do not expose patch to direct heat (heating pads, hot tubs, electric blankets).,Keep patch away from children and pets; dispose of used patches by folding adhesive side together and flushing down toilet.,Do not drink grapefruit juice as it may increase fentanyl levels.,Do not stop using patch suddenly as withdrawal symptoms may occur.,Report severe drowsiness, confusion, difficulty breathing, or constipation.,Store at room temperature away from moisture and heat.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-12 vs ABSTRAL, answered by our medical review team.
DURAGESIC-12 is a Opioid Analgesic that works by Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-12 and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-12 is: Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-12 and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-12 is classified as Category C. Pregnancy category C. First trimester: Limited data; theoretical risk of neural tube defects if folate deficiency exacerbated. Second and third trimesters: Risk of neonatal withdra. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.